Selected research
Industry Research
Polycystic Ovary Syndrome (PCOS) Drugs Industry Research Report 2026
Market perspective
The global Polycystic Ovary Syndrome (PCOS) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Polycystic Ovary Syndrome (PCOS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Polycystic Ovary Syndrome (PCOS) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Polycystic Ovary Syndrome (PCOS) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs include Teva Pharmaceutical Industries Limited, Sanofi, Novartis AG, Merck KGaA, Ferring Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc., Bristol Myers Squibb Co., BIOCAD and AstraZeneca plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Polycystic Ovary Syndrome (PCOS) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Polycystic Ovary Syndrome (PCOS) Drugs Market by Company
Teva Pharmaceutical Industries Limited
Sanofi
Novartis AG
Merck KGaA
Ferring Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
Bristol Myers Squibb Co.
BIOCAD
AstraZeneca plc.
Addex Therapeutics Ltd.
Polycystic Ovary Syndrome (PCOS) Drugs Segment by Type
Anti-Obesity
Antiandrogens
Antidepressant
Oral Contraceptives
Insulin-Sensitizing Agent
Polycystic Ovary Syndrome (PCOS) Drugs Segment by Application
Hospital
Clinic
Polycystic Ovary Syndrome (PCOS) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Polycystic Ovary Syndrome (PCOS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Polycystic Ovary Syndrome (PCOS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Polycystic Ovary Syndrome (PCOS) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Polycystic Ovary Syndrome (PCOS) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Polycystic Ovary Syndrome (PCOS) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Polycystic Ovary Syndrome (PCOS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-Obesity
- Antiandrogens
- Antidepressant
- Oral Contraceptives
- Insulin-Sensitizing Agent
Applications
- Hospital
- Clinic
Companies covered
- Teva Pharmaceutical Industries Limited
- Sanofi
- Novartis AG
- Merck KGaA
- Ferring Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc.
- Bristol Myers Squibb Co.
- BIOCAD
- AstraZeneca plc.
- Addex Therapeutics Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size (2021-2032)
- 2.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (2021-2032)
- 2.2.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Average Price (2021-2032)
- 2.3 Polycystic Ovary Syndrome (PCOS) Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anti-Obesity
- 2.3.3 Antiandrogens
- 2.3.4 Antidepressant
- 2.3.5 Oral Contraceptives
- 2.3.6 Insulin-Sensitizing Agent
- 2.4 Polycystic Ovary Syndrome (PCOS) Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Polycystic Ovary Syndrome (PCOS) Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Polycystic Ovary Syndrome (PCOS) Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Product Type & Application
- 3.8 Global Manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs, Established Date
- 3.9 Global Polycystic Ovary Syndrome (PCOS) Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries Limited
- 4.1.1 Teva Pharmaceutical Industries Limited Company Information
- 4.1.2 Teva Pharmaceutical Industries Limited Business Overview
- 4.1.3 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Limited Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis AG
- 4.3.1 Novartis AG Company Information
- 4.3.2 Novartis AG Business Overview
- 4.3.3 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.3.5 Novartis AG Recent Developments
- 4.4 Merck KGaA
- 4.4.1 Merck KGaA Company Information
- 4.4.2 Merck KGaA Business Overview
- 4.4.3 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.4.5 Merck KGaA Recent Developments
- 4.5 Ferring Pharmaceuticals, Inc.
- 4.5.1 Ferring Pharmaceuticals, Inc. Company Information
- 4.5.2 Ferring Pharmaceuticals, Inc. Business Overview
- 4.5.3 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.5.5 Ferring Pharmaceuticals, Inc. Recent Developments
- 4.6 Crinetics Pharmaceuticals, Inc.
- 4.6.1 Crinetics Pharmaceuticals, Inc. Company Information
- 4.6.2 Crinetics Pharmaceuticals, Inc. Business Overview
- 4.6.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.6.5 Crinetics Pharmaceuticals, Inc. Recent Developments
- 4.7 Bristol Myers Squibb Co.
- 4.7.1 Bristol Myers Squibb Co. Company Information
- 4.7.2 Bristol Myers Squibb Co. Business Overview
- 4.7.3 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.7.5 Bristol Myers Squibb Co. Recent Developments
- 4.8 BIOCAD
- 4.8.1 BIOCAD Company Information
- 4.8.2 BIOCAD Business Overview
- 4.8.3 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.8.5 BIOCAD Recent Developments
- 4.9 AstraZeneca plc.
- 4.9.1 AstraZeneca plc. Company Information
- 4.9.2 AstraZeneca plc. Business Overview
- 4.9.3 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.9.5 AstraZeneca plc. Recent Developments
- 4.10 Addex Therapeutics Ltd.
- 4.10.1 Addex Therapeutics Ltd. Company Information
- 4.10.2 Addex Therapeutics Ltd. Business Overview
- 4.10.3 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Product Portfolio
- 4.10.5 Addex Therapeutics Ltd. Recent Developments
5 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Scenario by Region
- 5.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2021-2032
- 5.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2021-2026
- 5.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Region: 2027-2032
- 5.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Region: 2027-2032
- 5.4 North America Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country
- 5.4.1 North America Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
- 5.4.3 North America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country
- 5.5.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country
- 5.7.1 South America Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
- 5.7.3 South America Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021-2032)
- 6.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021-2032)
- 7.1.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Polycystic Ovary Syndrome (PCOS) Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Polycystic Ovary Syndrome (PCOS) Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Polycystic Ovary Syndrome (PCOS) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Polycystic Ovary Syndrome (PCOS) Drugs Value Chain Analysis
- 8.1.1 Polycystic Ovary Syndrome (PCOS) Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Polycystic Ovary Syndrome (PCOS) Drugs Production Mode & Process
- 8.2 Polycystic Ovary Syndrome (PCOS) Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Polycystic Ovary Syndrome (PCOS) Drugs Distributors
- 8.2.3 Polycystic Ovary Syndrome (PCOS) Drugs Customers
9 Global Polycystic Ovary Syndrome (PCOS) Drugs Analyzing Market Dynamics
- 9.1 Polycystic Ovary Syndrome (PCOS) Drugs Industry Trends
- 9.2 Polycystic Ovary Syndrome (PCOS) Drugs Industry Drivers
- 9.3 Polycystic Ovary Syndrome (PCOS) Drugs Industry Opportunities and Challenges
- 9.4 Polycystic Ovary Syndrome (PCOS) Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst